Ordering
Available Variants25 mg
CHA.98490-25mg
Price
€270.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.98490-25mg | €270.40 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C26H33NO5 |
|---|---|
| CAS Number | 702681-67-2 |
| Molecular Weight | 439.54 |
| NACRES | NA.77 |
| PubChem Substance ID | 329823734 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD18452851 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS06
GHS09
  GHS06,GHS09
|
|---|---|
| signalword | Danger |
| hcodes | H301,H410 |
| pcodes | P264 - P273 - P301 + P310 - P391 - P405 - P501 |
| Hazard Classifications | Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 1 |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
CP-868388, also known by its CAS number 702681-67-2, is a potent and selective rho kinase inhibitor. This compound has been investigated for its potential therapeutic applications, particularly in the treatment of cardiovascular diseases and other conditions associated with smooth muscle contraction. By inhibiting the rho kinase enzyme, CP-868388 can induce vasodilation and reduce blood pressure, making it a promising candidate for the management of hypertension and related disorders. Additionally, its mechanism of action suggests potential benefits in the treatment of other conditions, such as pulmonary hypertension and heart failure. Further research is needed to fully elucidate the efficacy and safety profile of CP-868388, but its unique mechanism of action and preliminary data suggest that it may represent a valuable addition to the therapeutic arsenal for the treatment of cardiovascular diseases. Its pharmacological properties are being further explored.
